跳至主要内容
临床试验/CTRI/2020/08/027054
CTRI/2020/08/027054尚未招募未知

Study of the excess cost associated with drug wastage due to limited vial size options of the intravenous drugs for anti-cancer treatment, among patients receiving such treatment at Tata Memorial Hospital - CADWIACT

ot Applicable0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
ot Applicable

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Adult cancer patients
  • The patients advised and receiving any of the following 62 chemotherapy protocols will be included in the study.
  • Paclitaxel+-trastuzumab
  • Gemcitabine+carboplatin
  • Carboplatin+paclitaxel+/-Bevacizumab
  • Liposomal doxorubin
  • TCH(Docetaxel,carboplatin,trastuzumab)
  • SA Dactinomycin
  • SA Methotrexate
  • Cap-Irinotecan
  • SA Docetaxel
  • Panitumumab
  • Trastuzumab
  • Ramucirumab
  • Cape-Mitomycin
  • Gem-Oxaliplatin
  • Gem+cisplatin
  • Gem+nab paclitaxel
  • Pemetrexed+Cisplatin
  • Pemetrexed+Carboplatin
  • Pemetrexed-carboplatin+/- pembrolizumab
  • Gemcitabine+carboplatin
  • Paclitaxel+carboplatin
  • Geftinib+bevacizumab
  • Cisplatin+etoposide
  • Carboplatin+etoposide
  • SA Irinotecan
  • SA Gemcitabine
  • SA Paclitaxel
  • SA Docetaxel
  • Gemcitabine+cisplatin
  • Gemcitabine+carboplatin
  • Adult Hematology
  • Bendamustine-rituximab

排除标准

  • patients aged < 18 years

研究者

发起方
ot Applicable

相似试验